Seribantumab (
INN;[1] development code MM-121) is a monoclonal antibody designed for the treatment of cancer.[2] It binds to extracellular domain of
HER3 blocking
NRG1 binding and thereby preventing the activation of the receptor.[3]
This drug was developed by Sanofi/Merrimack Pharmaceuticals, Inc.
Seribantumab (
INN;[1] development code MM-121) is a monoclonal antibody designed for the treatment of cancer.[2] It binds to extracellular domain of
HER3 blocking
NRG1 binding and thereby preventing the activation of the receptor.[3]
This drug was developed by Sanofi/Merrimack Pharmaceuticals, Inc.